Metoprolol Retard Viatris (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in cardiac tissue. By inhibiting sympathetic stimulation, it decreases heart rate, myocardial contractility, and renin release from the kidneys, leading to reduced cardiac output and lower arterial pressure while improving heart‑failure symptoms.

The exact dose of Metoprolol Retard Viatris is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any comorbidities. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for metoprolol tartrate in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as metoprolol can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metoprolol Retard is a selective β1‑blocker, offering cardiac‑specific effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its extended‑release formulation provides once‑daily dosing, which can improve adherence relative to immediate‑release products that require multiple daily doses.

Metoprolol Retard should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain product stability.

Metoprolol Retard is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the extended‑release tablet whole; do not crush, chew, or split it, as this can alter the release profile and increase the risk of side effects.

Serious risks include severe bradycardia, heart block, profound hypotension, bronchospasm in patients with asthma or COPD, and worsening heart failure. Patients should be monitored for these events, especially during dose initiation or when combined with other cardiac‑active medications.

Metoprolol Retard is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and in individuals with uncompensated heart failure or severe peripheral vascular disease.